Report Overview

The global dry eye medication market size stood at around USD 3.7 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Rising laser surgeries, rising screen time, busy lifestyles, the increasing burden of diabetes, increase in prevalence of dry eye disease, promising pipeline for dry eye disease and side effects of other medications will drive market growth. Factors that could hinder the growth of the dry eye medication market in the future include long and costly drug approvals, stringent rules and regulations.



Market Drivers

Dry eye treatment market growth is driven by significant increase in the number of product launches considering the high prevalence of the disorder and potentially serious and chronic nature of the disease. The treatment of dry eye syndrome through therapeutics such as Xiidra (lifitegrast) and RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% may lead to an estimated cost of USD 5,000.0 per year. Despite such high costs, the severity of the disorder, which is considered to be one of the most common chronic ophthalmic disorders, is driving the adoption of these drugs. The increasing number of pipeline candidates in the pipelines of numerous major companies are anticipated to lead to certain regulatory approvals, further boosting the market size.